Skip to content
Peptide Spencer
Partner

Blend

GHK-Cu / BPC-157 / TB-500 / Epitalon

Custom strengths on request

Compounded medications are not FDA-approved.

What is in the vial

Blend calculator

Blend vial

Pick the blend, then the one component your dose is written for. The others follow from the vial.

mL
Dose is written for
mcg

Result

0102030405060708090100

Draw to

-

Water in the vial
-
Dose anchored to
GHK-Cu

What each component delivers

Amount of each blend component in the drawn dose
ComponentDelivered
GHK-Cu50 mg in the vial-
BPC-15710 mg in the vial-
TB-50010 mg in the vial-No established dose
Epitalon10 mg in the vial-

Math on the numbers above. Not medical advice; confirm concentration against the dispensed vial label.

Each component at a glance

GHK-Cu

These dosages are a helpful guide, not a prescription. Every clinician is expected to do their own due diligence before prescribing.

  1. Typical

    0.4% topical cream; no better than placebo (venous ulcer trial)

    Human study
Frequency
Twice daily (facial cream, women aged 50 to 59)
Route
Topical (facial, eye, thigh cream)
Course
12 weeks (facial and eye cream studies)
Topical data only; no injectable human trial was found. FDA flags compounded injectable GHK-Cu for immunogenicity risk (aggregation, impurities).
Calculate this dose

Full dosing guide

BPC-157

These dosages are a helpful guide, not a prescription. Every clinician is expected to do their own due diligence before prescribing.

  1. Start

    10 mg (total), injected around the inflamed bladder area during cystoscopy

    Human study
Frequency
Single procedure
Route
Around bladder inflammation during cystoscopy (reported as intravesical)
Course
Single administration; follow-up duration not stated
Human data are single 10 mg bladder-injection or 10 to 20 mg IV doses; no study tested repeated subcutaneous dosing.
Calculate this dose

Full dosing guide

TB-500

These dosages are a helpful guide, not a prescription. Every clinician is expected to do their own due diligence before prescribing.

No established human dose

No human or animal efficacy study of TB-500 (Ac-LKKTETQ) itself was identified. Trade press reports that FDA acknowledged 'there are no studies on TB500 itself'. Published work on the fragment is analytical, rat metabolism and in-vitro. Human trials exist only for full-length thymosin beta-4: an IV phase 1 study in healthy volunteers, ophthalmic RGN-259 dry-eye phase 2 trials (mixed efficacy, no safety issues reported), and topical dermal phase 2 trials in stasis and pressure ulcers. These data do not establish TB-500 dosing, safety or efficacy. Related full-length work not used for dosing includes a venous-ulcer design report and a recombinant human Tbeta4 STEMI study.

See the human studies

No allowed source gives TB-500 injectable dosing; human trials used full-length thymosin beta-4 by other routes and do not transfer.
Open the calculator

Full dosing guide

Epitalon

These dosages are a helpful guide, not a prescription. Every clinician is expected to do their own due diligence before prescribing.

  1. Start

    0.5 mg/day sublingual (placebo-controlled study, women)

    Human study
Frequency
daily
Route
sublingual
Course
20 days
Study routes were sublingual and parabulbar, not subcutaneous; no trial supports subcutaneous milligram dosing, and no dose-finding data exist.
Calculate this dose

Full dosing guide

Get a quote

Custom strengths on request. Prices are quoted per clinic.